Physician profile
Muhammad Javaid
NPI 1629500095
$2,317.58
in general payments reported to CMS, 2019-2025
21 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $201 · 2021: $803 · 2022: $540 · 2023: $262 · 2024: $175 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.40 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $540.27 | 2020-2025 | Bimzelx |
| Amgen INC. | $354.65 | 2021-2025 | Evenity |
| Sanofi-Aventis U.S. LLC | $349.97 | 2020-2024 | |
| Lilly USA, LLC | $170.70 | 2022 | |
| Glaxosmithkline, LLC. | $143.38 | 2020-2024 | Benlysta |
| Abbvie INC. | $117.39 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $108.09 | 2021-2023 | Lupkynis |
| Genzyme Corporation | $96.73 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $86.75 | 2021-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $79.21 | 2021-2023 | Saphnelo |
| Pfizer INC. | $46.42 | 2023 | |
| Novartis Pharmaceuticals Corporation | $38.51 | 2025 | |
| Radius Health, INC. | $37.21 | 2022-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $24.91 | 2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $20.91 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $19.73 | 2025 | Opsumit, Uptravi |
| Organon LLC | $17.95 | 2022 | |
| Genentech USA, INC. | $17.65 | 2020 | |
| Ani Pharmaceuticals, INC. | $17.54 | 2025 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $15.88 | 2024 | Injectafer |
| Janssen Biotech, INC. | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Javaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.